CATX Perspective Therapeutics, Inc.
Price Chart
Executive Summary
Perspective Therapeutics updated its corporate presentation on June 1, 2026, highlighting ASCO 2026 data for its 212Pb-based radiopharmaceutical pipeline. The filing is a routine update of investor materials with no new material financial information or definitive clinical results.
Actionable Insight
This filing is a routine corporate presentation update with no new material financial disclosures. Monitor upcoming regulatory catalysts (pivotal trial initiation for VMT-α-NET, further ASCO data) for tangible valuation events. No immediate trading action warranted.
Key Facts
- Perspective Therapeutics filed a corporate presentation as Exhibit 99.1 on June 1, 2026.
- Presentation highlights ongoing Phase 1/2a trials for VMT-α-NET (SSTR2+ NETs), VMT01 (MC1R melanoma), and PSV359 (FAP-α solid tumors).
- ASCO 2026 data analysis shows 'durable disease control' and 'best-in-class safety profile' for VMT-α-NET with n=68 patients.
- No financial results, guidance, or material definitive agreements were disclosed in this filing.
Financial Impact
No financial figures provided in the filing; pre-revenue clinical-stage biotech with no disclosed material financial impact.
Risk Factors
- Clinical-stage biotech with no approved products; regulatory and clinical execution risk.
- No revenue or profitability; reliance on capital markets for funding.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249594 |
| Document: catx-ex99_1.htm | 0001193125-26-249594 |
| Document: 0001193125-26-249594-index-headers.html | 0001193125-26-249594 |
| Document: 0001193125-26-249594-index.html | 0001193125-26-249594 |
| Document: 0001193125-26-249594.txt | 0001193125-26-249594 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
3d ago
|
Institutional Cluster
| $2.96 awaiting T+1 | awaiting T+1 | — | $2.95 (−0.34%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $2.96 awaiting T+1 | awaiting T+1 | — | $2.95 (−0.17%) |
|
Jun 3, 2026
11d ago
|
Press Release
| $3.56 $3.25 | ▼ −8.71% | ▼ −9.11% | $2.95 (−17.13%) |
|
Jun 1, 2026
13d ago
|
8-K
| $3.66 $3.60 | ▼ −1.64% | ▼ −1.78% | $2.95 (−19.40%) |
|
May 21, 2026
24d ago
|
Press Release
| $3.98 $4.16 | ▲ +4.52% | ▲ +3.94% | $2.95 (−25.88%) |
|
May 18, 2026
27d ago
|
Press Release
| $3.76 $3.63 | ▼ −3.46% | ▼ −2.81% | $2.95 (−21.54%) |
|
May 11, 2026
4w ago
|
8-K
| $3.77 $3.77 | · 0.00% | ▼ −0.54% | $2.95 (−21.75%) |
|
May 4, 2026
5w ago
|
8-K
| $3.65 $3.82 | ▲ +4.66% | ▲ +3.27% | $2.95 (−19.18%) |
|
Apr 24, 2026
7w ago
|
Press Release
| $4.51 $4.27 | ▼ −5.32% | ▼ −5.49% | $2.95 (−34.59%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $4.55 $4.64 | ▲ +1.98% | ▲ +2.63% | $2.95 (−35.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access